Genetics and Genomics for the Prevention and

Treatment of Cardiovascular Disease

This research is based on the update for genetics and genomics
for the prevention and treatment of cardivascular diseases. Although
there has been a decline of thirty percent in heart disease, it still
remains the leading cause of death among Americans. In general,
CVDs are complex diseases that have many genetic and enviromental
factors that contribute to the onset of them. There is major
investigation to identify more common forms of CVD and traits that
may be commonly related.
Genomics has many roles in cardiovascular heath and disease
that includes disease prediciton, genetic loci that influence CVD,
understanding mechanisms of genetic loci, and therapeutic target
idenfications. For people with single-gene CVD there has been many
useful diagnostic tests that allow us to inform family members and
patients. As far as developing genetic testing for complex CVDs this
has been minimal. This is because an individuals common links have
only little impact on risk. When studying genomics of complex CVD it is
challenged by influences of enviromental variables, phenotypic
heterogeneity, and pathogenic complexity.
The research they used in the earlier report was based on family
based linkages, single-gene or medelian mutations of relatively large

phenotypic effect sizes. Genome-wide association studies and wholegenome sequencing have allowed the ability for us to discover novel
genomic determinations of CVDs. GWAs and whole-genome
sequencings allows us to identify genes with previously unknown roles
in CVD.
The method they are using in the new update for GWAs is
analyzing single-nuclotide polymorphisms across the genome with a
case-control and continuous traits. They are also using exome and
genome sequencing which provides a strong research strategy for the
conditions that are pushed by uncommon variants.
They review the current state and knowledge we already have
obtained from CVDs which include coronary artery disease, stroke,
hypertension, and hypercholesterolemia. In this update they added
diabetes mellitus, inflammation, and pharmogenetics.